spending using Dartmouth Atlas of Health Care online data. Results: Among the 155,841 patients, 5.9% had a depression diagnosis within 30 days after AMI admission. DACC-based ADRs captured considerable variation in depression diagnosis (IQR: 0.74 -1.21) and relatively low and high zip code-level ADRs were dispersed across the United States. ADRs for depression diagnosis were statistically significantly related to Medicare spending (Pearson correlation coefficient = 0.14, p < 0.01), but not local physician supply. ConClusions: Substantial geographic variation in depression diagnosis exists across the United States. Areas with higher general healthcare spending were more likely to have higher depression diagnosis rates. Further research is needed to explore if geographic variation in diagnosis affect health and economic outcomes to address whether depression was correctly, overor under-diagnosed.
Disease-specific stuDiesDiabetes/enDocrine DisorDers -clinical outcomes studies pDb1 urinary tract infection among the sglt 2 inhibitors: a meta-analysis of 19 ranDomizeD controlleD trials
A293insufficient with monotherapy. We evaluated the cost and resource utilisation, in the UK health care system, of three treatment scenarios: tamsulosin (0.4mg) monotherapy; tolterodine (modified release, 4mg) + tamsulosin given concomitantly; and fixed-dose combination (FDC) of solifenacin 6mg + oral controlled absorption system [OCAS™] formulation of tamsulosin (TOCAS, 0.4mg). Methods: A Markov model, with a monthly cycle length and 1-year time horizon, compared the cost of treating 1,000 men with LUTS/BPH who have moderate-to-severe storage symptoms and voiding symptoms. All patients were initially treated with tamsulosin monotherapy. Patients with inadequately controlled symptoms at week 12, based on Total Urgency and Frequency Score (TUFS, the daily sum of all recorded Patient Perception of Intensity of Urgency Scale [PPIUS] scores from micturition diaries), were considered for FDC solifenacin 6mg + TOCAS or tolterodine + tamsulosin.Patients adequately controlled at week 12 continued tamsulosin monotherapy. Thereafter, patients could discontinue therapy each month based on reported medication persistence data. Patients who discontinued treatment were eligible for surgery or other medical management. Results: Compared with tamsulosin monotherapy, total costs per patient, over a 1-year time horizon, were reduced by £133.75 for tolterodine + tamsulosin and reduced by £154.85 for FDC solifenacin 6mg + TOCAS. ConClusions: Our findings suggest FDC solifenacin 6mg + TOCAS reduces annual health care costs compared with tamsulosin monotherapy and tolterodine + tamsulosin in patients with inadequately controlled storage symptoms. Lower total cost for FDC solifenacin 6mg + TOCAS and tolterodine + tamsulosin versus tamsulosin monotherapy was largely driven by improved symptom control. The relatively lower total cost for FDC solifenacin 6mg + TOCAS versus tolterodine + tamsulosin (£21 per patient/year) was principally due to improved persistence with FDC solifenacin 6mg + TOCAS.
A205pharmacists. The participants have demanded the Competition Act 2010 should be enforced effectively in current pharmacy practise. CONCLUSIONS: The unregulated pharmaceutical pricing issue had detrimental effect on the professionalism of community pharmacy practice in Malaysia. The study suggested that a medicine price regulation at the supply chain is needed to be implemented to curtail some unhealthy practice among Malaysian community pharmacists in future.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.